SereNeuro Therapeutics, a Johns Hopkins University spinout, announced the close of its pre-seed funding round. The Baltimore-based biotech is developing SN101, a non-opioid cell therapy that injects pain-sensing neurons into affected joints to treat osteoarthritis. The company also secured a $318,000 Small Business Innovation Research grant from the National Institutes of Health. The funding will support early development, translational science, and team expansion.
Company Information
Company
SereNeuro Therapeutics
Location
Baltimore, Maryland, United States
About
SereNeuro Therapeutics is a Johns Hopkins University spinout developing a non-opioid cell therapy called SN101 for osteoarthritis joint pain. The therapy injects pain-sensing neurons directly into affected joints to act as a 'pain sponge,' absorbing pain and inflammatory signals without the addiction risks of opioids. Founded in 2024, the company has secured pre-seed funding and an $318,000 SBIR grant from the National Institutes of Health. SereNeuro is preparing for an FDA meeting in November to begin formal development of its lead therapy candidate.
Fundz sees it the moment SereNeuro Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BaltimoreBiotechnologyHealth CareTherapeutics